Talk:Semaglutide

{{Talkheader}}

{{Reliable sources for medical articles}}

{{WikiProject banner shell|class=B|

{{WikiProject Pharmacology|importance=Mid}}

{{WikiProject Medicine |importance=Mid}}

{{WikiProject Chemicals|importance=Low}}

{{WikiProject Popular Culture|importance=|}}

}}

{{User:MiszaBot/config

| algo = old(360d)

| archive = Talk:Semaglutide/Archive %(counter)d

| counter = 1

| maxarchivesize = 125K

| archiveheader = {{Archive}}

| minthreadstoarchive = 1

| minthreadsleft = 5

}}

NYT article on using the drug for diabetes prevention

This is a respected secondary source discussing one study, so evaluate accordingly as per WP:MEDRS.

  • {{cite web |last=Blum |first=Dani |title=Ozempic Could Prevent Diabetes. Should We Use It For That? |website=The New York Times |date=2024-11-13 |url=https://www.nytimes.com/2024/11/13/well/ozempic-prediabetes.html |access-date=2024-11-16}}

Peaceray (talk) 21:11, 16 November 2024 (UTC)

Renal Benefits

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial - https://doi.org/10.1038/s41591-024-03133-0

Semaglutide seems to show some renal improvement with or without SGLT2 inhibitors in patients with ckd and T2DM. May be useful to add a section on renal protective effects. I'll defer to the community 12.50.9.2 (talk) 19:55, 16 December 2024 (UTC)

Trial method descriptions in "Clinical trials and early approvals for diabetes" section

{{Article link|Clinical trials and early approvals for diabetes}} describe double-blind and blind process in detail. Does the article really need this? I think linking is sufficient, as later sections do. --Naruyoko (talk) 17:23, 10 January 2025 (UTC)